-
Congratulations on the Successful Initiation of the GCK-01 Phase I Clinical TriaRecently, the Phase I Clinical Study to evaluate the Safety and Tolerability of GCK-01 Cell Injection Combined with Rituximab in Patients withRelapsed or Refractory Follicular Lymphoma, sponsored by Beijing Gecell Therapeutics, LLC., was officially launc2025/11/14 -
Gecell Becomes the First Internship Training Unit in Mainland China for the CapsRecently, Gecellhas achieved a significant development milestone - in June 2025, it officially became the first internship training unit in Mainland China for the Capstone Program of the National University of Singapore (NUS) Master's Program in Preci2025/07/24 -
Gecell Therapeutics’ patent is approved, and the innovation-driven development strategy gets paid backRecently, Gecell Therapeutics is awarded a Chinese national invention patent in the field of genome editing technology. This approved patent focuses on transposon-mediated knock-in of large-sized DNA into specific sites of genome, which effectively solves2025/02/19 -
Company Name Change AnnouncementDearpartners and friends:Due to the strategic developmental needs of the company, the company's main business body including theheadquarterhas been relocated to Beijing. Since January 2, 2025, the original "Shanghai Gecell Therapeutics" has2025/01/15 -
Congratulations! Gecell Therapeutics won the title of "Top 50 Most InnovativeOnJune16,2024,the2024IBIEXPOBioInnovativeDrugIndustryConference,coorganizedbyYimaikeandNanjingBiomedicalValley,cametoasuccessfulconclusiononthe15th.Onthesameday,theexciting"StarList"awardresultswereannounced.The"StarList"aimstodiscover2024/06/17 -
GCK01项目临床招募广告华中科技大学同济医学院附属协和医院 血液科 正在开展一项GCK-01细胞注射液联合利妥昔单抗治疗复发或难治性 B细胞非霍奇金淋巴瘤安全性和有效性的早期临床研究。该研究将主要评估GCK-01 NK细胞注射液联合利妥昔单抗治疗复发或难治性B细胞非霍奇金淋巴瘤患者的安全性和 耐受性。该研究已获得本院临床试验伦理委员会的批准，准备在本院开展临床研究，计划招募9-12例符合研究要求的受试者。若您符合以下条件，即可与我们联系...2023/12/06
